Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy

@inproceedings{Sarlo2013PhaseIS,
  title={Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy},
  author={Chiara Sarlo and Francesco Buccisano and Luca Maurillo and Mariagiovanna Cefalo and Luigi Di Caprio and Laura Cicconi and Concetta Ditto and Licia Ottaviani and Ambra Di Veroli and Maria Ilaria Del Principe and Maria Assunta Grasso and Daniela Nasso and Giovanna De Santis and S. Amadori and Adriano Venditti},
  booktitle={Leukemia research and treatment},
  year={2013}
}
We explored the safety and efficacy of bortezomib given as single agent in patients with untreated or relapsed/refractory acute myeloid leukemia (AML), unfit for conventional chemotherapy. Fourteen patients were treated with bortezomib 1.5 mg/m(2) administered twice weekly for two weeks, every 3 weeks. Median age was 70 years (range 60-81) and the median number of cycles delivered was 2 (range 1-4). Of 13 evaluable patients, in 8 (61%), the administration of bortezomib resulted in an… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
7 Extracted Citations
20 Extracted References
Similar Papers

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 20 references

S

  • W. Blum, S. Schwind
  • Tarighat et al., “Clinical and pharmacodynamic…
  • 2012
Highly Influential
3 Excerpts

Z

  • S. Liu, Z. Liu
  • Xie et al., “Bortezomib induces DNA…
  • 2008
Highly Influential
3 Excerpts

P

  • E. C. Attar, J. L. Johnson
  • C. Amrein et al., “Bortezomib added to…
  • 2013

Cytotoxic effects of bortezomib in myelodysplastic syndrome / acute myeloid leukemia depend on autophagy - mediated lysosomal degradation of TRAF 6 and repression of PSMA

  • P. de Fabritiis T. Caravita, A. Palumbo, S. Amadori, M. Boccadoro
  • Blood
  • 2012

A phase I clinical - pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias

  • V. H. Duong, E. F. Winton
  • Clinical Cancer Research
  • 2011

E

  • J. E. Lancet, V. H. Duong
  • F. Winton et al., “A phase I…
  • 2011
2 Excerpts

L

  • S. Liu
  • C.Wu, J. Pang et al., “Sp1/NFKappaB/HDAC/miR-29b…
  • 2010

Bortezomib induces DNA hypo - methylation and silenced gene transcription by interfering with Sp 1 / NF - κ B - dependent DNAmethyltransferase activity in acute myeloid leukemia

  • J. Pang
  • Blood
  • 2008

Similar Papers

Loading similar papers…